Merck (MRK) EBT Margin Growth (3y) (2012 - 2026)
Merck (MRK) EBT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 625.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -10.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 443.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -15,548.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -6,936.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -2,347.00 |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 456.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,137.00 |
| Mar 31, 2026 | -4,669.00 |
| Dec 31, 2025 | -455.00 |
| Sep 30, 2025 | 1,509.00 |
| Jun 30, 2025 | 88.00 |
| Mar 31, 2025 | 744.00 |
| Dec 31, 2024 | -222.00 |
| Sep 30, 2024 | -1,548.00 |
| Jun 30, 2024 | 2,222.00 |
| Mar 31, 2024 | 784.00 |
| Dec 31, 2023 | 926.00 |
| Sep 30, 2023 | 1,045.00 |
| Jun 30, 2023 | -6,479.00 |
| Mar 31, 2023 | -664.00 |
| Dec 31, 2022 | 6,160.00 |
| Sep 30, 2022 | 502.00 |
| Jun 30, 2022 | 304.00 |
| Mar 31, 2022 | 221.00 |
| Dec 31, 2021 | 523.00 |
| Sep 30, 2021 | 1,534.00 |